Top searches

PL

Resources

B2RLaw advises Proteon Pharmaceuticals on a strategic partnership with Skretting

01/02/2021

B2RLaw has advised Proteon Pharmaceuticals on a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry.

The companies will collaborate on developing products using bacteriophage technology to support aquaculture farmers as part of a holistic health strategy. The companies will work in a parallel R&D pipeline on the project.

The Partnership allows Proteon to grow its product portfolio in aquaculture and expand its presence worldwide. Both Proteon Pharmaceuticals and Skretting predict that the technology will become a valuable component of integrated management strategies on-farm with both feed and water applications under investigation.

Proteon Pharmaceuticals is a Polish originating biotech company with a vision to develop natural feed additives that help remove antibiotics from the food chain and improve animal and human health. The Company uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

Norwegian company, Skretting is the world’s largest producer of feeds for farmed fish. The Company has operations on five continents and produces 2.5 million tonnes of feed annually, for more than sixty species of fish. Skretting has 3,500 employees worldwide. Skretting has an R&D unit known as Skretting Aquaculture Research Centre (ARC) with the main objective to provide research and technical support regarding fish and shrimp feed. It has 140 employees representing 25 nationalities.

B2RLaw’s team advising Proteon Pharmaceuticals was led by Partner George Havaris and included Counsels Paulina Wyrostek and Malwina Niczke – Chmura.

George Havaris advises, “Proteon Pharmaceuticals is a Polish company that is well on the path to being a global leader in its field of operation. Animal health is a little-known industry in the wider public eye. However, animal health is fundamental to the health and well-being of humans. We congratulate Proteon and Skretting on this exciting Partnership and we look forward to continuing our support to Proteon on its growth path”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

10/01/2023

B2RLaw advises Polish unicorn DocPlanner on its acquisition of MyDr

B2RLaw has advised Polish unicorn DocPlanner on its acquisition of MyDr – DocPlanner’s first acquisition on the Polish market. Docplanner […]

MORE
02/01/2023

New Compliance 360 practice at B2RLaw

B2RLaw has established a multidisciplinary team whose aim is to support clients in monitoring and adapting their activities to the […]

MORE
28/11/2022

B2RLaw advises on the sale of award-winning Gdynia office complex

B2RLaw has advised the sellers (a Dutch company and Polish companies) on the sale of Łużycka Office Park (buildings A, […]

MORE
15/11/2022

B2RLaw advises SaaS-enabled B2B marketplace for the healthcare industry, Dentametr, on a pre-seed round with investors, which includes Octopus Ventures

B2RLaw has advised Dentametr and its founders on its pre-seed round capital raise with investors including leading investment fund Octopus […]

MORE
08/11/2022

B2RLaw advises Auxilius Pharma on capital raise to fuel groundbreaking growth to the US market

B2RLaw advised Auxilius Pharma Sp. z o.o. and its founders on a venture capital transaction related to the investment of […]

MORE
03/11/2022

B2RLaw advises Westcoast on merger to create EUR 5.5 billion ICT distributor

B2RLaw has advised the UK’s largest privately owned information and communications technology company Westcoast on Polish aspects of its merger […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close